BioNTech to price vaccine with Pfizer below market rates

  • 📰 thenewpaper
  • ⏱ Reading Time:
  • 21 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 12%
  • Publisher: 63%

대한민국 뉴스 뉴스

FRANKFURT: BioNTech, first in the race to produce evidence of a working Covid-19 vaccine together with Pfizer, is planning to price the two-shot regimen below 'typical market rates' and would differentiate pricing among countries or regions. But with tropical heat, remote...

But health experts cautioned that the vaccine, should it be approved, was no silver bullet - not least because the genetic material it is made from needs to be stored at temperatures of minus 70 deg C or below.

That is a problem given the World Health Organisation estimates 70 per cent of people must be inoculated to end the pandemic, and Asia alone is home to more than 4.6 billion - or three-fifths of the global population. "On the cold chain requirement of minus 70 deg, that is a hefty requirement. We do not have such a facility," Philippines' Health Secretary Francisco Duque told Reuters.

 

귀하의 의견에 감사드립니다. 귀하의 의견은 검토 후 게시됩니다.
이 소식을 빠르게 읽을 수 있도록 요약했습니다. 뉴스에 관심이 있으시면 여기에서 전문을 읽으실 수 있습니다. 더 많은 것을 읽으십시오:

 /  🏆 7. in KR

대한민국 최근 뉴스, 대한민국 헤드 라인